Multiple sclerosis: open trials in Belgium

20 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

NCT07067463
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Zenas BioPharma (USA), LLC
Hopital Erasme, Anderlecht · Universitair Ziekenhuis Gent, Gent · Noorderhart, Pelt · Nationaal Multiple Sclerose Centrum V.Z.W., Steenokkerzeel
Registry updated 2026-11-03
2023-504358-36-00
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Trial Treatment · Phase 3 · Sanofi-Aventis Recherche & Developpement
Universitair Ziekenhuis Gent, Gent · Noorderhart, Pelt
Registry updated 2026-10-28
NCT07299019
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Zenas BioPharma (USA), LLC
Algemeen Ziekenhuis Alma, Eeklo · Noorderhart, Pelt · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-10-27
NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Az St-Jan Brugge-Oostende A.V., Brugge · Noorderhart, Pelt
Registry updated 2026-10-26
2024-519304-28-00
Non-inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis.
Trial Treatment · Phase 3 · Sanofi-Aventis Recherche & Developpement
AZ ST-JAN Brugge A.V., Brugge · Universitair Ziekenhuis Gent, Gent · Algemeen Ziekenhuis Groeninge, Kortrijk · Noorderhart, Pelt · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-10-23
2024-512914-16-00
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Trial Treatment · Phase 3 · Amgen Inc.
Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-10-20
NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Novartis Investigative Site, Bonheiden · Novartis Investigative Site, Brussels · Novartis Investigative Site, Leuven · Novartis Investigative Site, Roeselare
Registry updated 2026-10-13
NCT07325292
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Trial Treatment · Phase 3 · Sanofi
AZ ST-JAN Brugge A.V., Brugge · Universitair Ziekenhuis Gent, Gent · Algemeen Ziekenhuis Groeninge, Kortrijk · Noorderhart, Pelt · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Nationaal Multiple Sclerose Centrum V.Z.W., Steenokkerzeel
Registry updated 2026-10-13
NCT07202195
At Home Use of Stimulation Suits for Managing MS Symptoms
Trial Treatment · Daphne Kos
Nationaal MS Center Melsbroek, Steenokkerzeel
Registry updated 2026-10-08
2024-511686-11-00
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Trial Treatment · Phase 3 · Novartis Pharma AG
Universitair Ziekenhuis Gent, Gent
Registry updated 2026-09-29
2024-512707-40-00
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
Trial Treatment · Phase 2 · Zenas Biopharma (USA) LLC
Noorderhart, Pelt
Registry updated 2026-08-27
NCT07788573
The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
Research · Université Catholique de Louvain
Université Catholique de Louvain, Brussels
Registry updated 2026-08-26
2025-521546-23-00
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Trial Treatment · Phase 3 · Novartis Pharma AG
Hopital Erasme, Anderlecht · Imelda, Bonheiden · UZ Leuven, Leuven · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-07-30
NCT07580820
Gait Adaptability in Persons With MS Having Mild Disability
Research · Hasselt University
REVAL Rehabilitation Research Center, University of Hasselt, Diepenbeek
Registry updated 2026-05-12
NCT05355389
Cognitive-motor Telerehabilitation in MS
Trial Treatment · Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel, Brussels · National MS Center Melsbroek, Melsbroek
Registry updated 2026-05-08
NCT07020715
A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
Trial Treatment · Phase 2 · University Hospital, Antwerp
Universitair Ziekenhuis Antwerpen, Edegem
Registry updated 2026-05-05
NCT07505355
Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis
Research · Hasselt University
REVAL Rehabilitation Research Center, Diepenbeek
Registry updated 2026-04-01
NCT05072691
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Research · Francis Corazza
CHU Brugmann, Brussels
Registry updated 2025-10-06
NCT07033975
A Specialized Diet for Multiple Sclerosis
Trial Treatment · Jerome J. A. Hendriks
Hasselt University, Diepenbeek
Registry updated 2025-06-24
NCT06966128
Transcranial Electrical Stimulation in Multiple Sclerosis
Trial Treatment · Universitair Ziekenhuis Brussel
University hospital of Brussels, Brussels · National MS Center Melsbroek, Melsbroek
Registry updated 2025-05-29

All Multiple sclerosis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error